Conference abstract · 23 Nov 2012
Conference abstract
Simvastatin solid lipid nanoparticles for improving the oral bioavailability
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
S tatins are HMG-CoA reductase inhibitors which are commonly prescribed to reduce the LDL-cholesterol. Statins lower cholesterol level through reversible and competitive inhibition of HMG-CoA reductase. An enzyme involved in the biosysnthesis of cholesterol and other sterols. Among all statins (atorvastatin, pravastatin, fluvastatin, cerivastain, lovastatins and simvastatin) Simvastatin and lovastatin exhibit poor oral bioavailability (< 5%). All statins undergo extensive microsomal metabolism by CYP enzymes. CYP3A4 is the major metabolizing enzyme that metabolizes lactone form of Simvastatin and significantly lower intestinal uptake. The hydrophobic properties of simvastatin prevent complete dissolution of the drug in the intestinal fluid which also contributing for its lower bioavailability. Solid lipid nanoparticles are alternative carrier system to polymeric nanoparticles. Solid lipid nanoparticles are in submicron size range (1 ? 1000 nm). SLN can be administered through oral, parentral, topical and pulmonary routes. Additional advantage of SLN include, lack of coalescences thus increase in physical stability. To overcome the hepatic first pass metabolism and to enhance the bioavailability, intestinal lymphatic transport of drugs can be exploited. In the present study attempt has been made to prepare solid lipid nanoparticles of simavastatin for improve the bioavailability. Solid lipid nanoparticles of simvastatin were prepared with triglycerides such as Trimyristin, Tripalmitin and Tristearin by hot homogenization followed by Ultrasonication method. The SLNs were characterized for size, zeta potential, entrapment efficiency, drug content and drug release. They were also evaluated by XRD, DSC for studying the interactions. Promising results of the study indicated the applicability of simvastatin solid lipid nano particles as potential tools for improvement of bioavailability of poorly soluble drugs PDF HTML
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 12 Dec 2025
Solid Lipid Nanoparticles to Improve Oral Bioavailability of Poorly Soluble Anticancer Agents
Research article · 20 May 2016
Simvastatin solid lipid nanoparticles for oral delivery: Formulation development and In vivo evaluation
Conference abstract
Relative bioavailability of oral insulin entrapped in solid lipid nanoparticles to subcutaneously administered insulin in diabetic rats
Review article · 15 Jul 2020
A Promising Approach for Improving Solubility and Bioavailability: Solid Lipid Nanoparticles
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “L. Srinivas”
- BylineArticles whose byline prints “P. Suresh”
- BylineArticles whose byline prints “K. Krishnam Raju”
- BylineArticles whose byline prints “K.V. Ramanamurthy”
